Lv41
450 积分 2025-07-27 加入
Use of liver stiffness measurement for hepatocellular carcinoma risk stratification in metabolic dysfunction associated steatotic liver disease
1小时前
已完结
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes
8天前
已完结
Impact of NAFLD and Fibrosis on Adverse Cardiovascular Events in Patients With Hypertension
9天前
已完结
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
10天前
已完结
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
10天前
已完结
Effect of Hypertension on Long-term Adverse Clinical Outcomes and Liver Fibrosis Progression in MASLD
16天前
已完结
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025
20天前
已完结
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
23天前
已完结
Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights
1个月前
已完结
Non‐hemodynamic effects: Repurposing of nonselective beta‐blockers in cirrhosis?
1个月前
已完结
皖公网安备34019202002308
